Aptahem’s lead candidate Apta-1 preliminary does not show any toxicity in the GLP tox studies
Aptahem AB (publ) announces today that the GLP (Good Laboratory Practice) toxicology and safety studies preliminary show positive results. The studies are the final part of the preclinical program before an application to start clinical studies can be filed. Preliminary results show that the pharmaceutical candidate Apta-1 was well tolerated within the estimated dose window. A time consuming analytical work will now start to compile all the data from the studies and the company estimates to be able to communicate the final reports later in 2021.Aptahem has now finalized the practical part